Financings

Aclarion (ACON) sells 506,803 shares at $9.25 in a $4.7 million offering

ACON

Aclarion, Inc. agreed on January 30, 2025 to sell 506,803 shares at $9.25 each, for about $4.7 million gross, through Dawson James Securities, Inc. as placement agent.

Investor Chat

Scorecard

ACONEquity
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-08
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 5.3/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

Equity: common stock

Warrant coverage0%

By the aibio.space news desk

A boardroom table with chairs and a laptop
A boardroom table with chairs and a laptop. CC0, via rawpixel. The picture shows the field, not the companies named.

Aclarion, Inc. (Nasdaq: ACON) agreed on January 30, 2025 to sell 506,803 shares of common stock in a registered direct offering at $9.25 a share. The company disclosed the deal in a Form 8-K filed January 31, 2025. Gross proceeds were expected to be about $4.7 million before placement agent fees and other offering expenses.

Why is this important: The sale adds about $4.7 million of gross proceeds to a company whose quarterly report for September 2024 said its liquidity raised substantial doubt about its ability to continue as a going concern. The shares were sold at a fixed price through a placement agent, so existing holders absorb the new shares at that price. Cash on hand was about $1.3 million at September 30, 2024, which makes this raise a large share of the company's near-term funding.

John Lorbiecki, the chief financial officer, signed the 8-K. In our view, a company with about $1.3 million of cash and a going-concern doubt in its latest quarterly report should not expect rounds of this size to carry operations for long. The filing gives shareholders no say in the price. The stated use of proceeds covers market development and clinical evidence, product development and quality, and general and administration support, with no dated plan attached to any of them.

What the offering costs shareholders

The company's placement agency agreement with Dawson James Securities, Inc., dated January 30, 2025, pays the agent a cash fee of 7% of aggregate gross proceeds and reimburses certain of its expenses. The 8-K names Dawson James as the exclusive placement agent. The prospectus supplement adds that the company will reimburse the agent up to a maximum of $40,000 of expenses. The 8-K puts gross proceeds at about $4.7 million, so the agent's fee and the offering costs make the net figure smaller than the headline. The 8-K describes the deal as a registered direct offering, sold to purchasers named in a purchase agreement.

The 10-Q for the quarter ended September 30, 2024 gives the company's liquidity position at that date. It reports cash and cash equivalents of $1,312,098. The report says there is uncertainty about the company's ability to maintain liquidity, which raises substantial doubt about its ability to continue as a going concern, and that the company will need to raise additional funds.

The prospectus supplement describes a past working capital deficiency, a stockholders' deficit and recurring losses from operations as the basis for that doubt. It says that, regardless of the amount of net proceeds raised in this offering, the company will require additional financing in the future to continue as a going concern. Its independent registered public accounting firm included an explanatory paragraph in its report on the 2023 financial statements. For shareholders, that sentence matters more than the headline figure. The filing treats the next raise as a given.

The lead product and what the filings say about it

The 10-Q describes Aclarion as a healthcare technology company. Its product is the NOCISCAN report, and the prospectus supplement says the company is addressing the chronic low back pain market, with a focus on the lumbar spine. The 10-Q says revenue for the quarter fell mainly because clinical activity at customer sites using NOCISCAN reports ended, offset in part by an increase in patient-pay reports.

The prospectus supplement says the company captures both raw spectroscopy data and post-processed spectral data from every NOCISCAN completed, to use as future training data for a machine learning algorithm that links MRS data to clinical outcomes. The company calls that use of AI aspirational. That is a plan for future work, not evidence of a clinical effect. The filing gives no ClinicalTrials.gov number for any study of NOCISCAN, and the proceeds are stated to fund market development and clinical evidence, which suggests the company still needs that evidence.

What comes next

The 8-K sets no date for the next financing and names no milestone that the proceeds must reach. The filing does not state a date for a trial start or a commercial target. Readers should check the next quarterly report for cash, losses and any new financing terms before drawing conclusions about the company's runway. The stated uses of proceeds give shareholders a yardstick for measuring that report against this one.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.